Abstract
Concurrent chemo-radiotherapy (CCRT) followed by adjuvant durvalumab (D) represents standard of care for fit patients (pts) with unresectable stage III NSCLC. Aim: assess whether intensity modulated proton therapy (IMPT), compared to intensity modulated photon therapy (IMRT) can reduce lymphopenia (primary endpoint), and other toxicities; and whether IMPT affects immune related adverse events (irAEs) incidence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
